Dennis Oyieng'o, MD
Pulmonary Disease · Wichita, KSNPI 1629207766
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,500 of the $9,151 with a category attached, or 60.1%. Intuitive Surgical accounts for 76.1% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $7,067, more than ten times the $198 reported in 2019.
Across 40 payments — averaging $228.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- GSK$695
- Inari Medical, Inc.$329
- AstraZeneca$236
- Boehringer Ingelheim$184
- Abbott$146
- plus $600 from 6 others
What the payments were for
- Travel & lodging$1,32314%
- Food & beverage$2,32825%
- Education$5,50060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $6,961 |
| GSK | 16 | $695 |
| Inari Medical, Inc. | 3 | $329 |
| AstraZeneca | 2 | $236 |
| Boehringer Ingelheim | 2 | $184 |
| Abbott | 1 | $146 |
| Sanofi | 2 | $144 |
| Amgen | 1 | $111 |
| United Therapeutics Corporation | 1 | $106 |
| Actelion Pharmaceuticals US, Inc. | 1 | $96 |
| Atricure, Inc. | 1 | $92 |
| Veran Medical Technologies, Inc. | 2 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,922
- TEZSPIRE$347
- DUPIXENT$250
- FLOWTRIEVER CATHETER, S$247
- CT THROMBECTOMY SYSTEM KIT$247
- MitraClip System$146
- NUCALA$125
How this compares
$9,151 in reported general payments places this provider in the 80th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 307 | $216,518 |
| Spiriva RespimatTiotropium Bromide | 69 | $54,133 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 87 | $52,627 |
| Breo ElliptaFluticasone/Vilanterol | 74 | $40,908 |
| Ambrisentan | 16 | $38,968 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $14,282 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $9,665 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $9,564 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $8,285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 203 | $5,473 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $5,103 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,155 |
| Ventolin HfaAlbuterol Sulfate | 30 | $1,758 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,633 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $695 | $319,616497 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $184 | $62,41782 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $236 | $23,94763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Victor SalloumWichita$14K
- Ibrahim RaphaelWichita$13K
- Nader EldikaWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Youssef YammineWichita$6K
- Raid Abu-AwwadWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.